Eviola, diagnosed 2012
Basal-IQ Technology
The easy choice to help protect from lows.

 
 

When life gets busy, the fear of going low can really get in your way. Our Basal-IQ predictive low-glucose suspend technology can help you spend less time worrying about lows and more time living your life.

Responsive Insulin Delivery

Basal-IQ® technology predicts and helps prevent lows. It can turn insulin delivery on and off as often as every 5 minutes. There is no minimum insulin suspension period.

 

Works Silently in the Background

No added alerts or alarms beyond standard continuous glucose monitoring (CGM) and pump notifications.* Users must only decide if they want the feature turned on or off.

 

t:slim X2 Insulin Pump with Basal-IQ Technology

 
 

 

31%

Less time low

Relative reduction in sensor time below 70 mg/dL when clinical study participants used Basal-IQ technology.1

 

91%

Said it's easy to use

Percent of clinical study participants who said the Basal-IQ feature on the t:slim X2™ insulin pump was easy to use.1

 

 
 

How it works

Basal-IQ technology uses Dexcom G6 CGM values to help reduce the frequency and duration of low-glucose events by predicting glucose levels 30 minutes ahead and suspending insulin if they are expected to drop below 80 mg/dL or if a CGM reading falls below 70 mg/dL. Insulin delivery resumes as soon as sensor glucose values begin to rise.

Basal-IQ_Illustration_1140x600

 
 

2300x1440_tslimX2_CGM_System_wShare

Zero Fingersticks

Dexcom G6 CGM integration with the t:slim X2 pump provides exceptional accuracy2 for optimized insulin delivery. Dexcom G6 is the first real-time, integrated continuous glucose monitoring (iCGM) system requiring zero fingersticks for calibration or mealtime dosing.

‡ If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

2300x1440_Service_Rep

So what's next?

Whether you're ready to get the t:slim X2 insulin pump or just looking to check your insurance coverage, everything you need is right here.

Get Started

 

Upgrade program

If you are currently using a non-Tandem pump for your insulin therapy and are interested in upgrading to the t:slim X2 pump, take advance of our pump upgrade program.  Learn More

 

Try out the t:slim X2 insulin pump with our free demo app

Search for the t:simulator™ application wherever you download apps, or click the badges below to visit the download page for your device.

AppBadge_AppleStore Google Play

 
 

Notes Icon

Responsible Use of
Basal-IQ Technology

Systems like the t:slim X2 insulin pump with Basal-IQ technology are not substitutes for active diabetes management, as there are common scenarios in which automated systems cannot prevent hypoglycemia. The Basal-IQ feature relies on continuous CGM readings and will not be able to predict glucose levels and suspend insulin delivery if your CGM is not working properly or is unable to communicate with your pump. Be sure to always use your pump, cartridges, CGM, and infusion sets as instructed and check them regularly to make sure they are working properly. Always pay attention to your symptoms, actively monitor your glucose levels, and treat according to your healthcare provider’s recommendations.

 
 

* Users have the option to request alerts when insulin is suspended and when it resumes. Patients will receive standard CGM alerts and alarms related to low glucose levels that require attention.
† Dexcom CGM sold separately. Transmitter can only be paired with one medical device (either a Dexcom receiver or t:slim X2 insulin pump) and one consumer device (phone or tablet) at the same time.
‡ If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

References
1. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161.